<DOC>
	<DOCNO>NCT02531113</DOCNO>
	<brief_summary>The purpose determine whether RPC1063 effective treatment Crohn 's disease .</brief_summary>
	<brief_title>Efficacy Safety Trial RPC1063 Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description>This open-label trial compose two period : Induction Extension . All eligible patient enrol 12-Week Induction period receive study medication . Patients complete Induction period may eligible enter 100-Week Extension period continue receive study medication .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Crohn 's disease ( CD ) confirm endoscopy histology Active disease evaluate Crohn 's Disease Activity Index Score Simple Endoscopic Score CD Inadequate response aminosalicylates , corticosteroid , immunomodulators biologic therapy Key Diagnosis ulcerative colitis indeterminate colitis Known strictures/stenosis lead symptom obstruction Current stoma need ileostomy colostomy Clinically relevant cardiovascular condition relevant disease could impact implementation interpretation trial , put patient risk History uveitis know macular edema History colonic dysplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>